VVTMF (VVT Med) ROE %: 0.00% (As of Sep. 2025)


VVTMF VVT Med Inc VVTMF
6 GF Score
Price $0.02
! 4 Warning Signs
View Full Analysis

What is VVT Med ROE %?

VVT Med VVTMF 6 ROE % is 0.00% as of Sep. 2025. GuruFocus rates VVTMF with a GF Score™ of 6/100. The stock has 4 warning signs investors should review. Among 797 Medical Devices & Instruments companies, VVT Med ranks worse than 125470.39% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. VVT Med's annualized net income for the quarter that ended in Sep. 2025 was $-8.90 Mil. VVT Med's average Total Stockholders Equity over the quarter that ended in Sep. 2025 was $-2.52 Mil. Therefore, VVT Med's annualized ROE % for the quarter that ended in Sep. 2025 was N/A%.

The historical rank and industry rank for VVT Med's ROE % or its related term are showing as below:

VVTMF's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.4
* Ranked among companies with meaningful ROE % only.

VVT Med  (OTCPK:VVTMF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2025 )
=Net Income/Total Stockholders Equity
=-8.904/-2.523
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-8.904 / 0.028)*(0.028 / 1.624)*(1.624 / -2.523)
=Net Margin %*Asset Turnover*Equity Multiplier
=-31800 %*0.0172*N/A
=ROA %*Equity Multiplier
=-546.96 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2025 )
=Net Income/Total Stockholders Equity
=-8.904/-2.523
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-8.904 / -8.904) * (-8.904 / -8.844) * (-8.844 / 0.028) * (0.028 / 1.624) * (1.624 / -2.523)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0068 * -31585.71 % * 0.0172 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2025) net income data. The Revenue data used here is four times the quarterly (Sep. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


VVT Med ROE % Related Terms


VVT Med ROE % Historical Data

* Premium members only.

The historical data trend for VVT Med's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VVT Med ROE % Chart

VVT Med Annual Data
Trend Dec22 Dec23 Dec24
ROE %
0.00 0.00 0.00

VVT Med Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
ROE % Get a 7-Day Free Trial Premium Member Only 0.00 Negative Equity 0.00 0.00 0.00

VVTMF vs ABT, SYK, MDT: ROE % Comparison

For the Medical Devices subindustry, VVT Med's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VVT Med ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VVT Med's ROE % distribution charts can be found below:

* The bar in red indicates where VVT Med's ROE % falls into.


VVTMF
6GF Score
VVT Med Inc VVTMF
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VVT Med ROE % Calculation

VVT Med's annualized ROE % for the fiscal year that ended in Dec. 2024 is calculated as

ROE %=Net Income (A: Dec. 2024 )/( (Total Stockholders Equity (A: Dec. 2023 )+Total Stockholders Equity (A: Dec. 2024 ))/ count )
=-1.04/( (-5.356+-6.38)/ 2 )
=-1.04/-5.868
=N/A %

VVT Med's annualized ROE % for the quarter that ended in Sep. 2025 is calculated as

ROE %=Net Income (Q: Sep. 2025 )/( (Total Stockholders Equity (Q: Jun. 2025 )+Total Stockholders Equity (Q: Sep. 2025 ))/ count )
=-8.904/( (-4.47+-0.576)/ 2 )
=-8.904/-2.523
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2025) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
VVT Med (VVTMF) has a ROE % of 0.00% as of Sep. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on VVT Med and its competitors. According to the industry distribution chart, VVT Med ranks #999999 out of 797 companies in the Medical Devices & Instruments industry.
Is VVT Med's ROE % too high?
VVT Med's current ROE % is 0.00%. Based on the distribution chart, VVT Med ranks #999999 out of 797 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, VVT Med has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does VVT Med's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VVT Med ranks #999999 out of 797 companies for ROE %. This places VVT Med in the lower half of its industry. The industry median ROE % is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on VVT Med and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VVT Med's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VVT Med stock overvalued right now?
VVT Med (VVTMF) has a current ROE % of 0.00%. The current ROE % is 0.00%. VVT Med's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For VVT Med (VVTMF), the current ROE % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VVT Med Business Description

Other Exchanges VVTM:Canada
Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
VVT Med Inc is a medical device company, focused on developing and commercializing a range of minimally invasive technologies for treating varicose veins. VVT's research and development activities are based in Israel. The company proudly boasts three products within its portfolio that have achieved commercial production status and are currently available in the market. These products have undergone meticulous design processes, obtaining regulatory approvals across multiple countries.
6GF Score

Get the complete analysis for VVTMF

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price